Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inhibikase Therapeutics Inc (NQ: IKT )

2.730 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 905
Open 2.730
Bid (Size) 2.730 (21)
Ask (Size) 2.900 (1)
Prev. Close 2.730
Today's Range 2.730 - 2.730
52wk Range 0.8500 - 3.820
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga

Performance

YTD
+104.99%
+104.99%
1 Month
+3.41%
+3.41%
3 Month
+96.90%
+96.90%
6 Month
+50.83%
+50.83%
1 Year
+197.77%
+197.77%

More News

Read More
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Dow Surges 350 Points; US Crude Oil Stocks Increase
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Crude Oil Edges Lower; US Wholesale Inventories Rise 0.1% In August
Via Benzinga
Exposures Fossil Fuels
Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today
Via Benzinga
Dow Jumps Over 100 Points; Helen Of Troy Posts Upbeat Q2 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
From Inhibikase Therapeutics
Via GlobeNewswire
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.